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Abstract
The role of radiation therapy in cancer management is first defined:
today among the cancer patients who are cured ( @  45 %) about one half
are cured by radiation therapy applied alone or in combination with
surgery or chemotherapy.  The experience accumulated in decades
shows that, to be efficient, the radiation treatment must be delivered
with a high physical selectivity.  At present, electron linear accelerators
are the primary equipment of a modern radiotherapy department, and a
large proportion of the patients are treated with a linear accelerator for at
least part of the treatment.  Photon beams of about 6-20 MV have, in
general, a sufficient penetration in the tissues to treat most of the
tumours with an  adequate physical selectivity.  A single beam is never
used alone, but a combination of several beams adequately oriented
allow the radiation-oncologist to deliver the prescribed dose to the target
volume without exceeding the tolerance of the surrounding normal
tissues.  Modern linear accelerators also allow us to apply electron
beam therapy.  Electron beam therapy is suitable for the treatment of
superficial lesions (e.g., skin tumours) and is also the best available
irradiation treatment for Intra-Operative-Radiation-Therapy (IORT).
Finally, conformation therapy, which is  developed in many well-
equipped and well-staffed centres, will probably further improve, in the
near future, the efficiency of linear accelerators at least for some tumour
locations.
1 . INTRODUCTION — ROLE OF RADIATION THERAPY IN CANCER
MANAGEMENT
Electron linear accelerators today constitute the core of the equipment of a modern
radiation therapy department.  Nowadays, the majority of the patients referred to a radiation
therapy department are treated with a linear accelerator for at least part of their treatment.  It is
likely that this will remain true for the foreseeable future.  Linear accelerators thus play, and will
keep playing, a significant role in cancer management in general and are responsible for the
therapeutic success obtained in many tumour treatment.  To illustrate the situation, Table 1 gives
the number of linear accelerators at present used in France for radiotherapy applications (their
type and energy).  The numbers of the other radiotherapy units are also given for comparison
[1].
Cancer has an increasing impact on the death rates in the Western world, as well as in the
developing countries.  For example, in 1980, 730 000 deaths were  attributed to cancer in the
countries of the European Union and there were 1 186 000 new cancer cases diagnosed in that
year alone [2, 3].  These estimates exclude non-melanoma skin cancer, which, although a rare
cause of death, nevertheless demands medical care.  Even with the current prevention programs,
the numbers will further increase within the next two decades.  Similar figures have been
published for North America.
Table 1
Number of radiotherapy units in France, on 1 January 1994 1)
A.  LINEAR ACCELERATORS
GECGR Mev Other companies Total
4-6 MV NEPTUNE 6
ORION 5














Philips (SL 18) 4 34



















20-25 MV SATURNE 111 4 4
25 MV SATURNE 43 35 Philips (SL 75/25) 9 44
Total Linear Accelerators 157 51 208
(+ 19)
B.  OTHER TYPES OF RADIATION THERAPY UNITS
RX 50-100 kV
RX 150-305 kV
Cobal Units (including 1 gamma knife)
Betatrons
Cyclotron neutron therapy
Cyclotron neutron + protontherapy
Synchrotron protontherapy
116    (-6)
 34     (-8)
144   (-19)
   1     (-2)
   1
   1
   1
1)  The differences since 01.01.1993 are given (+) or (-)
Today, at the first consultation, approximately 65% of the patients have apparently
localized tumours.  About 2/3 of these are cured either by surgery, radiotherapy, or a
combination of both treatments.  In this group of patients with probable but unproved subclinical
metastatic disease, chemotherapy used as an adjutant treatment may prolong life and maybe cure
some additional patients.
Among the other 35% of patients arriving at the first consultation with already inoperable
or metastatic disease, only about 5% will be cured by combined treatment including
chemotherapy and immunotherapy as well as radiotherapy and/or surgery (Table 2).  Although
there is promising progress in the field of medical oncology, this cure rate is largely limited to
solid paediatric tumours, leukaemias, lymphomas, and testicular tumours.  These tumours
represent only about 5% of all cancers seen in a general population [4-6].  Although these
percentages [5] are useful as an indication of the contribution of the different techniques to
cancer cure, they will become progressively less relevant to the extent that combination of these
different techniques is more and more successfully applied.
It is axiomatic that one must control the local disease if one aims ultimately at curing any
cancer patient. In fact, it has been shown that 1/3 of the patients who die of cancer had
uncontrolled local disease.  If local failure could be reduced by 50%, one could expect a
10-15% improvement in cure rate [7].
Surgical techniques have already reached a very high level. Further improvement will be
seen in a reduction of mutilating procedures (limb-sparing operation, breast-conserving therapy,
reduction of colostomies, and urinary diversions).  On the other hand, wider excisions are still
foreseeable as a result of safer anaesthesiology, intensive care support, and improvement in
reconstructive surgery.
Table 2
Summary of the present situation concerning cancer cure rate
Patients Cure  rate %
With localised tumour:
   cured by surgery
   cured by radiotherapy





With inoperable or metastatic disease:




Furthermore, the combination, on a wider scale, of surgery with irradiation will help to
increase the local control rate.  In that respect, Fletcher (M.D. Anderson Hospital, Houston) has
shown that, after radical surgery, doses of 50 Gy given over 5 weeks are able to eradicate
expected occult infestation ("subclinical disease") in the lymphatic nodes for cancer of the breast,
upper respiratory and digestive track and some pelvic tumours, in more than 90% of the cases.
Doses of 50 Gy do not exceed the tolerance limit of many normal tissues.
Today, about 70% of the cancer patients are referred to a radiation therapy department,
either for a radical treatment (aiming at a local control) or after surgery (also aiming at a local
control) or for a palliative treatment often in combination with chemotherapy (e.g., a painful
bone metastasis) [8].
2 . RATIONALE FOR RADIATION THERAPY
Soon after the discovery of x-rays by Röntgen in 1895 and of radium by Marie Curie in
1898, it became evident that ionizing radiations could sterilise malignant tumours and thus cure
cancer patients.  It also became rapidly evident that, above a certain dose level, x-rays induce
damage to the normal tissues they traverse.
The effects produced by radiation are not instantaneous.  In particular, tumour shrinkage
after irradiation is a process extending over weeks or even months.  This is due to the fact that
cells, doomed to die, do not disappear immediately: they remain present for hours or days;
sometimes they are able to undergo a few divisions before disintegration and elimination.  This
progressive tumour shrinkage reduces the risk of acute complications, such as haemorrhage after
electro-coagulation. It is a major advantage of irradiation for cancer management [9].
Since local control probability increases with dose, radiation must reach the whole
volume(s) of tissues invaded by malignant cells at a sufficiently high dose level to be effective.
This goal must be reached without inducing severe and irreversible sequelae in the surrounding
normal tissues.  A first approach to reach this goal is the improvement of the physical selectivity.
2 . 1 Physical selectivity of a therapeutic irradiation
The physical selectivity of irradiation is defined as the ratio of the dose to the "tumour"
relative to the dose to the surrounding "normal tissues".  It can be improved by varying the
nature and energy of the radiation or the beam arrangement (number and orientation of the
beams, and their size and shape as in conformation therapy).
The best historical illustration of the importance of the physical selectivity in radiation
therapy is the impressive improvement in the clinical results achieved in the 1950's–60's when
200 kV x-rays (orthovoltage) were replaced by cobalt-60 gamma rays and high-energy x-rays,
as shown in Table 3.  The high-energy x-rays mentioned in this table are x-rays ( ‡  2–3 MV)
produced by Van de Graaff machines, betatrons or electron linear accelerators.  Linear
accelerators have played an important role in the improvement of the physical selectivity in
radiation therapy in the last decades, as will be discussed in detail in the following sections.
Table 3
Improved survival of patients with several types of cancer treated with megavoltage radiotherapy
Survival (%) after
Type of cancer 200 kV x-rays High-energy x-rays
Hodgkin's disease
Cancer of the cervix







Cancer of the bladder
Cancer of the prostate
Seminoma of the testis









Cancer of the nasopharynx








From the Conquest of Cancer, Report of the National Panel of Consultants of the Committee on
Labor and Public Welfare United States Senate, November 1970, p. 51 [9].
Today, with modern techniques, most critical normal tissues such as brain, eyes, spinal
cord, kidneys, liver, etc. may be completely avoided or at least irradiated at levels well below
tolerance (except, of course, in special cases depending on the tumour location:  e.g. the normal
brain is the normal tissue at risk when a brain tumour is treated, similarly the spinal cord is the
normal tissue at risk when some cervical or mediastinal tumours are treated, etc.).
Physical selectivity is a second specific advantage of radiation therapy compared to
chemotherapy in which all the tissues in the body are exposed to the toxic drug.
The real situation is however more complex.  Outside the limits of the detectable tumour
(i.e. the "gross tumour volume" as defined below), there is in general some "subclinical"
involvement.  A larger tissue volume must then be irradiated: not only the gross tumour volume
itself but also a surrounding safety margin and, in some cases, the regional lymph node areas.
Several types of volumes thus have to be defined and identified.
2 . 2 Concepts and definitions of volumes used in radiation therapy
Gross Tumour Volume (GTV)
Radiation oncologists first identify the gross tumour volume (GTV), which is the gross
palpable or visible extent and location of the cancer disease (ICRU Report 50, [10]).  The shape,
size and location of the GTV is determined by means of different diagnostic methods such as
clinical examination (e.g., inspection, palpation, endoscopy) and various imaging techniques
(e.g., x-ray, CT, ultrasound, MRI, etc.).  The gross tumour volume consists mainly of
malignant cells, connective tissue and blood vessels, and necrotic areas.
Clinical Target Volume (CTV)
Clinical experience has shown that around the GTV there is in general "subclinical
involvement", i.e., individual malignant cells, small cell clusters, or microextensions which
cannot be detected by the clinical or imaging procedures.  Thus a safety margin surrounding the
GTV must  be irradiated to ensure local control of the disease.  The size of the safety margin
depends on the type of tumour, its location, and its tendency to invade the surrounding normal
tissues (histology, grading, etc.).  The GTV together with this safety margin consisting of
tissues with presumed or proven subclinical involvement is defined as a Clinical Target Volume
(CTV).
In addition to the safety margin around the tumour, other volumes with presumed or
proven subclinical spread (such as regional lymph nodes) may also require irradiation.  The
Clinical Target Volume is thus the tissue volume that contains a demonstrable GTV and/or
presumed/proven subclinical microscopic malignant disease.  This volume must be treated at an
adequate dose level (and time-dose pattern) to achieve the aim of therapy, cure, or palliation.
Planning Target Volume (PTV)
To ensure that all tissues included in the CTV receive the prescribed dose, one has, in
principle, to plan to irradiate a volume geometrically larger than the CTV.  It is the Planning
Target Volume or PTV.
The additional safety margin, included in the PTV, results from a number of factors:
- movements of the tissues which contain the CTV (e.g., with respiration), as well as
movements of the patient.
- variations in size and shape of the tissues that contain the CTV (e.g., different
fillings of the bladder, rectum, stomach).
- all variations and uncertainties in beam geometry and patient-beam geometry.  There
are some uncertainties in the beam sizes, shapes and directions, as well as in the
relative position of the beam with respect to the patient, the CTV and the normal
tissues.
- all uncertainties in dose distribution, especially in or close to the penumbra region,
or where inhomogeneities have to be taken into account (e.g., beam penetration for
electron beams).
Delineation of the PTV is a matter of compromise and depends upon the judgement of the
radiation-oncologist, who ultimately bears the responsibility for this decision.  In particular, too-
large safety margins will result in unnecessary side effects and complications.
2 . 3 IMPROVEMENT OF THE DIFFERENTIAL EFFECT.  A PROBLEM FOR
THE RADIOBIOLOGIST
As defined above, the safety margins contained in the CTV and in the PTV consist
primarily of normal tissues and, only for a small proportion, of invading cancer cells.  Because
of the presence of these cells, the safety margin should be irradiated in principle to the highest
possible dose to prevent a local recurrence, but the tolerance of the normal tissues included in the
safety margin limits the dose which can be prescribed.
The difficulty cannot be solved by improving the physical selectivity of the irradiation; it
requires an improvement of the differential effect, and this brings us from the field of physics to
the field of radiobiology.  Improvement of the differential effect implies, for a given (physical)
dose, increasing the effect of the cancer cell population and/or reducing the effects on the normal
tissues [11, 12].
The possibility of improving the differential effect by adequately selecting the irradiation
parameters is the third advantage of radiation therapy for cancer management.
Historically the first, and presently the most efficient, method for improving the
differential effect was the fractionation of the dose, as initiated in 1919 by Regaud, Ferroux and
Coutard at the Fondation Curie in Paris.  Today, five fractions of 2 Gy each per week are used
as the conventional fractionation for most treatments.
As a further refinement, the fractionation could be adapted to the growth characteristics of
the individual tumour (such as, the tumour doubling time, or better the potential doubling time,
TPOT).  In that respect, an EORTC study has shown that a shorter overall time brings a benefit
for some head and neck tumours with short TPOT.  This implies the administration of several
small (£  1.5 Gy) fractions per day, since large fraction sizes are known to be harmful.
Combination of radiation with radiosensitizers is another method to improve the
differential effect.  Drugs such as misonidazole are used to sensitize selectively hypoxic cancer
cells.  Other drugs, such as actinomycin D, bleomycin, adriamycin, 5-fluorouracil, and, more
recently, cis-platinum have been used as radiosensitizers in the treatment of oesophagus, lung,
or intestinal tumours.  Besides any synergistic effects, radiation and drugs have several
complementary actions which further justify their therapeutic association.
A third possibility for improving the differential effect is to replace x-rays (and other low-
LET radiations) by high-LET radiations (ICRU Report 45 [10]).  High-LET radiations bring a
benefit for well-differentiated, slowly growing tumours and/or for tumours containing a large
proportion of hypoxic cancer cells [13-15].
2 . 4 ACCURACY REQUIRED IN RADIATION THERAPY
Whatever the improvement in the radiobiological differential effect, the doses which are
needed to control a malignant tumour are often of the same order of magnitude as the tolerance
doses for the normal tissues.  In addition, radiobiological and clinical evidence indicates that the
dose-effect relations for tumour control are steep (Table 4) [16–18].  For some tumours, a dose
variation of a few percent can modify significantly the observed local control rate.  The dose-
effect relations are even steeper for normal tissue complications (Table 5) [17]. For these two
reasons, accurate dosimetry is needed, and, in 1976, the ICRU made the following
recommendations: "the available evidence for certain types of tumours points to the need for an
accuracy of –  5% in the delivery of an absorbed dose to a target volume if the eradication of the
primary tumour is sought" (ICRU Report 24 [10]).  More recently (1987), Mijnheer et al. [17]
recommended an accuracy in absorbed dose delivery of 3.5% (one standard deviation, for the
dose at the specification point, for radical treatment).
Over the years, the ICRU has played an important role in the world-wide improvement of
dosimetry in radiation therapy.  An important step in that direction was the definition of
quantities and of a system of units (ICRU Report 33 [10]).  Besides quantities and units, the
ICRU has focused a great part of its efforts on the selection of procedures suitable for the
measurement and application of these quantities.  This implies a critical review of the existing
procedures, value judgement, and finally the recommendation of selected procedures. These
should  be well described and codified, and widely accepted in the different countries.
Several ICRU Reports have dealt with dosimetry protocols for photon therapy:  Reports
14, 17, 23, 24 and 42 [10].  For electron beam therapy, Report 35 remains a world-wide
reference.  Other ICRU Reports have contributed to a better accuracy and uniformity of
dosimetry procedures in radiation therapy:  Reports 44, 46 and 48.
Table 4
Relative steepness of the dose-effect curve for local tumour control.  The steepness is expressed
as the relative increase in absorbed dose (in %) producing a change in tumour control probability
from 50 to 75%.
Site of tumour Steepness (%)
Supraglottic larynx T2 and T3 (Shukovsky)
Larynx T3 (Stewart and Jackson)




Larynx all stages (Hjelm-Hansen et al.)
Bladder T4B (Battermann et al.)




Supraglottic larynx T1 and T2 (Ghossein et al.)
Skin and lip (Strandqvist)




Nasopharynx T1 and T2 (Tokars and Griem)
Nasopharynx (Moench and Philips)




Retromolar trigone/anterior faucial pillar T1 and T2 (Thames et al.)
Bladder all stage (Morisson)




Tonsillar fossa T3 and T4 (Thames et al.)
Hodgkin (Kaplan)





Relative steepness of the dose-effect curve for normal tissue reaction  The steepness is expressed
as the relative increase in absorbed dose (in %) from 25% to 50%
Normal tissue reaction Steepness (%)
Major chronic complications of the larynx (Harwood and Tierie)
Peripheral neuropathy (Stoll and Andrew)




Late intenstinal damage (Battermann et al.)
Brachial plexus (Svensson et al.)




Skin reaction (Turesson and Notter)
Major complications of the intestine and bladder (Morrison)




Myelitis (Phillips and Buschke)
Major and non major complications of the larynx (Ghossein et al.)
15
17
3 . SHORT DESCRIPTION OF A MEDICAL LINEAR ACCELERATOR
In medical linear accelerators, the charged particle is an electron and the RF accelerating
electric field oscillates at about 3000 MHz.  For comparison, radio waves in standard amplitude
modulation broadcast channels oscillate at about 1 MHz [19].  
The electrons are thermo-ionically emitted from a concave metal cathode at 1000 ˚C and
accelerated in the gun to about 1/4 the velocity of light by a pulsed dc electric field.  They are
then formed (coalesced) into a pencil beam by a convergent electric field between the gun
electrodes.  The RF electric field in the accelerating tube then forms the electron stream into
bunches and accelerates them to more than 99% of the velocity of light, increasing their mass
(e.g., by a factor of 13 at 6 MeV).  The electrons then bombard the target (e.g., tungsten).
When an electron enters a tungsten target, the positively-charged nuclei of the tungsten atoms
pull on the negatively-charged electron, shaking it violently as it passes by one such tungsten
atom after another.  These high-energy electrons give up a portion of the energy at each
successive atom that they penetrate and emit hard, penetrating x-rays in the forward direction.
Two sets of tungsten blocks allow the sizes of the radiation beam (square or rectangular
sections) to be adjusted.
All modern medical electron linacs employ an isocentric gantry.  The accelerator wave
guide is mounted in the gantry, either (relatively) parallel to the gantry axis if a beam bending
magnet is employed, or perpendicular to the gantry axis if a beam bending magnet is not
required (low energy, e.g. 4 MV x-ray beam).  A simplified block diagram of a medical linear
accelerator is presented in Fig. 1.
More and more modern linear accelerators are equipped with a multileaf collimator which
typically consists of two sets of 20 leaves which can be moved independently allowing the
application of irregularly-shaped beams better adapted to the complex shape of the target volume
(Fig. 2) [20].
Fig. 1  Simplified block diagram of a medical linear accelerator
4 THERAPY WITH HIGH-ENERGY PHOTON BEAMS
The most important characteristics of a therapeutic photon beam are the penetration in the
irradiated tissues (depth/dose curve), the skin sparing effect and the penumbra.  For clinical
applications, a single beam is seldom applied; and, for each patient, the optimal combination
involving several (or many) photon beams has to be selected.
Fig. 2  Principle of a multileaf collimator.  It consists of two sets of 20 leaves which can be
moved and adjusted independently.  As a result, beams of any shape can be applied to closely
match the shape of the target volume.  Target volumes with complex shapes can be treated with
minimum irradiation of the surrounding normal tissues [20].
4 . 1 Beam penetration — depth/dose curves
The penetration of the beam increases with energy (Fig. 3).  The depth/dose curves
describe the variation of absorbed dose (relative to the maximum dose) as a function of depth, in
the irradiated medium, on the beam axis.
Fig. 3  Depth/dose curves for therapeutic photon beams of different energy.  Low-energy x-ray
beams (100 kV) are still in use and are suitable for treating skin lesions.  Orthovoltage x-rays
(200-500 kV) are totally inadequate to treat deep seated tumours;  they are nearly completely
abandoned.  Cobalt-60 is satisfactory for many clinical situations but x-ray energies between 8
and 24 MV are needed to obtain adequate depth dose/curves.  In addition to an improvement of
the beam penetration with energy, there is a sparing effect which also increases with energy.
Epidermis only is spared with cobalt-60 but the subcutaneous tissues are also protected with 8-
24 MV photons.
X-rays of about 100 kV ("low-energy" x-rays) are still in use, but only for the treatment of
superficial (skin) lesions.  Conventional x-rays ("orthovoltage", 200-250 kV) were the only
treatment available up to 1955–1960, before cobalt-60, betatrons and linear accelerators were
available.
Cobalt-60 provides irradiation conditions which are satisfactory for a large proportion of
clinical situations.  Cobalt-60 emits gamma rays at 1.17 and 1.33 MeV respectively.  Due to the
simple construction of the machine, cobalt units are the ideal equipment for developing
countries.
Linear accelerators of about 8 MV and above allow most of the tumours to be treated with
good physical selectivity.  There is no clear advantage in increasing the x-ray beam energy
beyond 20-24 MV.
The importance of beam energy in irradiating deep seated tumours is better illustrated on
Fig. 4, where the doses are normalized at the depth of the centre of the target volume.  
Fig. 4  The depth/dose curves for different photon beam energies are normalized at 12 cm in
depth (e.g. difficult situation for an obese patient).  This presentation better illustrates the
excessive dose delivered to the normal tissues located in front of the PTV when 200 kV x-rays
or (to a lesser extent) cobalt-60 are used.
4 . 2 Skin sparing
When only 200 kV x-rays were available, the acute skin reactions often prevented the
radiation-oncologist from delivering the appropriate dose to the deep seated tumours.
For photon energies higher than 2–3  MV, the maximum absorbed dose is not observed at
the surface of the irradiated medium, but a few millimetres below the surface.  This skin sparing
effect is due to a lack of "electronic equilibrium" (ICRU 24 [10]).
For cobalt-60, the acute skin reactions are dramatically reduced.  Furthermore, for photon
energies of about 8 MV and above, there is a significant reduction of the absorbed doses at the
level of the subcutaneous tissues which reduces the risk of late fibrosis.  A reduction of the
absorbed dose at the level of the subcutaneous tissues also facilitates healing of the surgical
wound if surgery is  needed after irradiation.
4 . 3 Penumbra
Ideally, the absorbed dose within the geometrical limits of the photon beam should be
homogeneous and the absorbed dose outside the beam as low as possible.  Unfortunately, at the
border of the beam, there is a narrow region with a steep dose gradient:  it is the "penumbra
region".
The penumbra width is defined, at a given depth, as the distance between two selected
isodose levels, i.e., between the 80% and 20% isodoses or between the 90% and 10% isodoses
(100% being the maximum absorbed dose on the beam axis at that depth).  In all cases, the two
isodose levels used for defining the penumbra should be specified (Fig. 5).
Fig. 5  Dose distribution obtained with a single 8 MV photon beam (beam size 10 cm x 10 cm).
Transverse section through the patient body;  the planning target volume (PTV) is indicated by
the hatched area.  The dose is specified at the centre of the PTV (100%), it varies within the
PTV from 114% to 86%.  From ICRU 50 [10].
4 . 4 Beam combination
An acceptable dose distribution cannot be achieved with only a single photon beam.  The
normal tissues in front of the target volume receive too high a dose, and the normal tissues
behind the target volume also receive a significant dose (see again Figs 3 and 4).
In the "cross-fire" technique, several beams that intersect at the level of  the target volume
are used;  as a result, the surrounding normal tissues at risk are irradiated only by one beam.
The number and the orientation of the beams are selected by the radiation-oncologist; it is a
matter of judgement and experience to select the optimal beam arrangement for each particular
patient.  Some examples of treatment schemes are presented in Figs 6–9.
5. ELECTRON-BEAM THERAPY
Besides photon-beam therapy, modern linear accelerators allow electron-beam therapy to
be applied.  For that purpose, in the accelerator head, the target is removed and the beam of
accelerated electrons is directly oriented towards the patient and the PTV.
Fig. 6.  Transverse section through the
pelvis, with the display of the dose
distribution resulting from four beams:  two
sets of two parallel opposed beams
orthogonal to each other ("box technique").
The PTV is indicated by the hatched area.
The dose is specified (100 %) at the centre
of the PTV and on the beam axes.  The dose
within the PTV ranges from 103 % to 95 %.
This beam arrangement can be used for the
treatment of a locally-extended cervix
carcinoma.  From ICRU 50 [10].
Fig. 7.  Transverse section through the
thorax, with the display of the dose
distribution resulting from a moving beam
treatment with an 8-MV photon beam (large
arc 300° ).  The PTV is indicated by the
hatched area.  The dose is specified at the
centre of the target volume (100 %) and on the
central axis of the moving beam.  The dose
variation within the PTV ranges from 102 %
to 80 %.  This irradiation technique can be
used e.g. for the treatment of a mediastinal
tumour (oesophagus as presented in the
figure) or a prostatic tumour.  From ICRU 50
[10].
Fig. 8  Three equally weighted 8-MV photon
beams are converging towards the centre of
the PTV.  Wedge filters (45 ° ) are used for
beams # 2 and 3 to achieve a homogeneous
dose distribution throughout the PTV.  From
ICRU 50 [10].
Fig. 9  Irradiation of a lateral lesion (e.g.
floor of the mouth).  Two orthogonal 8-MV
beams with 45°  wedge filters are used.
From ICRU 50 [10].
5 . 1 Electron beams
The penetration of the electron beams in the tissues is much shallower than that of the x-
ray beams and, in addition, can be adjusted by varying the energy of the incident electrons
(Fig. 10).  Therefore, electron-beam therapy is used to treat superficial or semi-deep-seated
tumours extending (close) to the skin surface.  Beyond the depth of the maximum, the dose falls
off rapidly (but to a lesser extent when the initial energy increases).  Figure 11 presents, as an
example, the dose distribution for a 20 MeV electron beam.  Treatment energies range from
about 4 to 20–25 MeV, but some accelerators reach higher energies (e.g., 35 MeV for a
Sagittaire and 50 MeV for the race-track microtron).
Fig. 10  Central-axis depth/dose curves for
electron beams of different energy, from 6
to 22 MeV (field size:  10 cm x 10 cm;
source/skin distance:  100 cm).  The steep
fall-off of the dose, especially at the low
energies, protects the normal tissues located
beyond the PTV.
Fig. 11  Isodose curves for a 20 MeV electron
beam in a water phantom (10 x 10 cm;
source/skin distance:  100 cm).  Scattering of
the electrons in the medium is responsible for
the widening of the isodose curves with
increasing depth.
Electron beams are used for 10–25 % of the patients referred to the radiation therapy department,
this proportion varying from country to country and from centre to centre depending on the local
treatment policy.  Electrons are often used in combination with photon beams (e.g., as a boost
against the residual tumour).  Two specific applications of electron beams deserve to be
mentioned.
5.2.1  Total skin electron therapy
A skin cancer, mycosis fungoides, is most often treated in this way.  The aim of the basic
treatment is to irradiate the total skin envelope as homogeneously as possible.  The depth of the
lesions suitable for this type of treatment varies with the stage and type of disease and/or the
body surface.  This may lead to the use of different beam penetrations.  When tumourous
lesions are present, there may be a need for a special boost and/or shielding.
The maximum depth of the PTV varies from approximately 5 to 15 mm in most of the
lesions.  For the most frequent indications, with localised and even generalized plaques, the
PTV is located within the first 5 mm.  Infiltrated plaques, ulcerations, and tumourous lesions
justify an individual estimate of the thickness of the lesions whenever possible.
Different technical approaches have been developed using multiple fields, arc therapy,
patient rotation, patient translation, according to the available local equipment and facility
(Figs 12, 13) [21].  In the past, low-energy x-rays were the only possibility, but they tend to be
less frequently used since the implementation of low-energy electron beam techniques using
linear accelerators.  As a general rule, the integral dose should be kept as low as possible.
Usually, the incident electron beam energy at the level of the patient skin ranges from 3 to 7
MeV with nominal energy ranging from about 4 to 10 MeV (i.e., accelerator energy at the exit
window).  Such energy losses are due to the material in the treatment head, the air gap between
the exit window and the patient,  and the use of scattering screens.  The use of scatter energy
degrader (typically a 1 g. cm-2 lucite panel) close to the patient improves dose uniformity,
particularly on oblique body surfaces, and results in a higher surface dose and shallower depth
dose due to the increase of the angular spread of the original electron beam.
Fig. 12  Total skin electron therapy – six field
arc therapy. Geometry of the treatment set-up
of electron arc therapy, showing the arc
direction.  Distribution of the six fields for full
circumferential coverage is also indicated on a
typical transverse section.
Fig. 13  Total skin electron therapy.  Patient
stances for the anterio, posterior, and two
of the angled dual-field exposures.
5.2.1  Intra-operative radiation therapy (IORT)
With this technique, electron beams are used to deliver a large single-dose fraction during
surgical procedure to a well defined PTV.  The dimensions of the CTV are defined accurately by
the surgeon and the radiation oncologist together.  During the procedure, mobile sensitive
tissues are displaced out of the beam using localizers, in order to decrease normal tissue toxicity.  
The purpose of the procedure is usually to treat presumed subclinical disease after
macroscopically radical resection.  The exact shape, size and location of the CTV can thus only
be defined during surgery.
Different types of localizers have been described, according to the local equipment and
facilities.  The dose distribution depends strongly on the design of such localizers, applicators,
and other accessories, as well as on patient/beam positioning accuracy.  Most irradiation
techniques involve lucite applicators linked physically to the head of the treatment machine
(docking system), but systems using laser beams and an optical set up (non-docking system) are
also in use (Figs 14, 15).
In general, the nominal incident electron beam energy ranges from 6 to 20 MeV (beam
energy at the exit window), giving energies between 3 and 15 MeV at the patient surface.
Flattening filters are used to provide a homogeneity of –  10 % within the geometrical beam; they
also act as scattering foils leading to additional decrease in the beam energy at the patient level.
Nominal energy thus becomes irrelevant,  and beam quality can only be described using
depth/dose distribution on the geometrical axis of the beam (assuming an homogeneous phantom
parallel to the applicator end). In some cases, combination of adjacent beams has to be used to
treat a PTV larger than the available localizers.
Fig. 14  Shematic drawing of the Lyon IORT
system
Fig. 15  Electron beams for IORT.  The
dose distribution varies with the localizer, in
particular with the angle between the
localizer (or beam) axis and the distal plane
of the localizer  (perpendicular or oblique,
left and right figure respectively).  With an
oblique beam, a higher electron energy is
needed to treat a given tissue thickness.
6 . THE FUTURE:  NEW DEVELOPMENTS AND TRENDS IN RADIATION 
THERAPY
As mentioned above, the efficiency of radiation therapy may be improved either by
increasing the differential effect, the physical selectivity, or both.
Several attempts have been made to improve the "radiobiological differential effect":
– optimizing the fractionation scheme as a function of the characteristics of the
individual tumours;
– combining radiation with new radiosensitizing drugs, but also selecting their optimal
combination (e.g., time schedule for administration of both radiation and drugs).
However, it is probably through the development of new irradiation techniques that the
most significant progress may be expected.  An increase in total dose to the target volume,
without exceeding the tolerance dose of the surrounding normal tissues, has always been the key
to a better clinical result [7, 16, 18].  
A promising approach is the replacement of conventional x-rays by new types of radiation,
at least for some tumour sites.  Among them, fast neutrons and protons are the most commonly
used, and, to a lesser extent, heavy ions.
Fast neutrons, which are high-LET radiation, aim at improving the differential effect
(ICRU Report 46 [10]).  Radiobiology has shown that they are specifically efficient against
hypoxic (cancer) cells or against cells which accumulate in the resistant phases of the mitotic
cycle.
Recently, clinical observation has shown that neutrons bring a benefit for the treatment of
some well-selected types of tumours [13, 14, 22].  The most convincing results were obtained
for locally-extended inoperable salivary-gland tumours for which the conclusions of a NCI
study are summarized as follows:  "fast neutron radiation therapy alone is the treatment of choice
for salivary-gland tumours that cannot be completely resected and/or where the surgical risk of
facial nerve damage is high" [15, 23].  Also, for locally extended prostatic adenocarcinoma, two
randomized trials, initiated by the RTOG in the US, have shown the superiority of fast neutrons
(used alone or as "mixed schedule") compared to conventional x-rays [23, 24].
Proton-beam therapy improves the physical selectivity of the irradiation, but no benefit is
to be expected from an improved differential effect [7].  However, the impressive clinical results
obtained for selected tumour sites (in particular, uveal melanoma) by the pioneer centres have
encouraged several other centres to initiate proton therapy programs.  The number of proton-
therapy facilities is increasing:  4 in 1980, 6 in 1985, 10 in 1990,  and 16 in 1994.  Other
facilities are planned.
Technological development has allowed the engineers to offer cyclotrons that are compact,
reliable, and affordable.  These compact cyclotrons, superconducting or based on conventional
technology, can be installed within the hospital. They will soon certainly facilitate the
development of neutron- and proton-beam therapy.
Heavy ions combine the advantages of neutrons and protons: they enable the radiation
oncologist to deliver a high-LET  therapeutic irradiation with an excellent physical selectivity
comparable to that of proton beams.  Heavy ions were applied at the Lawrence Berkeley
Laboratory, where 299 patients were treated with neon ions.  Unfortunately, the facility was
closed recently.  However, an ambitious heavy-ion therapy program was started at the NIRS in
China, Japan, in 1994.  A third program will start at the GSI in Darmstadt, Germany, in 1996.
Unfortunately, for the present and the near future, the number of patients who could
benefit from these new types of beams will be limited.  Therefore, it is important to improve and
to optimize the available techniques.  In that respect, stereotactic radiosurgery, conformation
radiotherapy, intra-operative radiotherapy, total skin irradiation, and modern developments in
brachytherapy have already brought encouraging results for some tumour types.  These
techniques are being applied in an increasing number of large, well-equipped and well-staffed
radiotherapy departments.  Their safe application requires accurate dosimetry and careful quality
control procedures.  Some of these approaches (e.g., stereotactic radiosurgery and conformation
radiotherapy) involve optimizing the use of linear accelerators and improving their technical
characteristics.
Stereotactic radiosurgery is used mainly for the treatment of lesions limited in size and
located in the head (e.g., tumours of the base of the skull).  By using a large number of narrow
beams intersecting at the level of the lesion or by using arc therapy, high doses can de delivered
to the lesion while keeping the dose to the surrounding normal structures relatively low.  This
procedure requires accurate localization of the lesion, accurate dose computation, and accurate
beam/patient positioning (Fig. 16) [25].
Conformation therapy can be defined as an effort to optimize the treatment by adequately
selecting the number and orientation of the beams, their size and shape.  In other words, the
volume of tissues actually irradiated should match as closely as possible the PTV, even if it is
complex in shape.
Since the early days of radiation therapy, some kind of conformation therapy was an
objective.  Impressive examples were given already in the forties, for example by Baclesse and
his colleagues at the Fondation Curie in Paris, especially for some tumours of the head and neck
area.  However, the poorly penetrating beam available at that time prevented the full success of
these efforts.
a) b)
Fig. 16  Stereotactic radiosurgery.  a) Overview of patient treatment.  A special collimator and an
accurate head support system is added to the linear accelerator.  Treatment uses both gantry and
turntable rotation.  b) Head schematic showing the three coordinate axes and the four arcs of a
typical cranial treatment  [25]
Today, four sets of new means are available to the radiation-oncologist:
a) complete patient data:  typically in the form of a series of CT slices with detailed
anatomical information (MRI or other imaging techniques).  The location, extent and
position of the target volume relative to the organs at risk or anatomical reference points
can be known accurately.
b) with high-energy, penetrating x-ray beams, it is possible to reach any point in the body,
even in depth.  Furthermore, the beams are well collimated; their size and shape can be
adapted to the target volume.  With complex beam arrangements, different beam shapes
can be applied.
c) with the modern treatment planning systems (3-D), it is possible, even for a complex
treatment, to visualise rapidly the resulting dose distribution and thus to optimize the beam
arrangement based on reliable information.  
d) lastly, with some sophisticated equipment, the treatment machine can be driven
automatically by the computer of the treatment planning system.
An example of the possible development in the field of conformation therapy is given in
Fig. 17 where the target volume consists of the iliac and para-aortic lymph node areas.  In
different transverse planes, the shape of the target volume and its position relative to the patient
contour and reference anatomical points vary significantly.  This implies that the optimum beam
arrangement (number and orientation of the beams) may be different within the different
transverse planes.  Furthermore, in a given plane, since the target volume is not spherical in
shape, the size and shape  of the beams should  be different according to their orientation [26].
Other approaches are possible, combining for example beams which are no longer coplanar.
Fig. 17  Example of conformation therapy.  Dynamic treatment is used to irradiate a PTV
consisting of the retroperitoneal para-aortic lymph nodes as well of the iliaque lymph nodes. In
each  transverse section, the number, size, shape and orientation of the beams is optimized.
Irregular-shaped beams can be used.  The movements of the gantry, treatment head, and
collimator are computer controlled.  There is, in addition, a slow (computer-controlled) patient
translation [26].
In conclusion, an optimal use of the available modern linear accelerators, in particular
conformation therapy,  will improve the outcome of the radiotherapy treatments in well-selected
patient groups.  The side effects and complications will certainly be reduced.  Optimization of
the treatments with linear accelerators will be facilitated by further improvement in their technical
performance and reliability.  In addition, several companies have designed specific types of
linear accelerators for specific purposes (e.g. stereotactic radiosurgery) [25, 27].
Finally, the techniques of stereotactic radiosurgery and conformation therapy described
above can be combined with the introduction of new beam qualities (e.g. protons, neutrons,
heavy ions).  The benefit of both approaches could then be added.  Application of neutron,
proton and heavy-ion beams using conformation therapy techniques has actually been achieved
in some centres for certain well-selected tumour types [24, 27].
*     *     *
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